Kia Washington
Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Eye | 4 | 2016 | 98 | 2.030 |
Why?
| Facial Transplantation | 4 | 2022 | 9 | 1.600 |
Why?
| Blindness | 3 | 2016 | 37 | 1.580 |
Why?
| Tacrolimus | 5 | 2024 | 134 | 1.430 |
Why?
| Vascularized Composite Allotransplantation | 3 | 2023 | 22 | 1.280 |
Why?
| Vibrissae | 3 | 2022 | 10 | 1.050 |
Why?
| Myelin Sheath | 2 | 2024 | 144 | 0.830 |
Why?
| Nerve Regeneration | 6 | 2024 | 50 | 0.760 |
Why?
| Optic Nerve Injuries | 2 | 2017 | 4 | 0.710 |
Why?
| Tissue and Organ Harvesting | 2 | 2016 | 62 | 0.660 |
Why?
| Rats | 14 | 2024 | 4958 | 0.620 |
Why?
| Organ Transplantation | 2 | 2016 | 159 | 0.550 |
Why?
| Peripheral Nerve Injuries | 2 | 2018 | 32 | 0.540 |
Why?
| Somatosensory Cortex | 2 | 2022 | 32 | 0.520 |
Why?
| Transplantation, Homologous | 6 | 2020 | 377 | 0.520 |
Why?
| Neurons, Afferent | 1 | 2016 | 85 | 0.500 |
Why?
| Retina | 1 | 2016 | 263 | 0.470 |
Why?
| Composite Tissue Allografts | 2 | 2022 | 8 | 0.410 |
Why?
| Adaptation, Physiological | 1 | 2016 | 483 | 0.400 |
Why?
| Graft Rejection | 5 | 2022 | 513 | 0.390 |
Why?
| Surgery, Plastic | 2 | 2020 | 25 | 0.330 |
Why?
| Hindlimb | 5 | 2023 | 130 | 0.330 |
Why?
| Tissue Transplantation | 1 | 2009 | 11 | 0.320 |
Why?
| Animals | 18 | 2024 | 31709 | 0.310 |
Why?
| Craniofacial Abnormalities | 1 | 2009 | 59 | 0.310 |
Why?
| Neurons | 3 | 2024 | 1280 | 0.280 |
Why?
| Urethane | 1 | 2024 | 41 | 0.220 |
Why?
| Carbamates | 1 | 2024 | 34 | 0.220 |
Why?
| Urea | 1 | 2024 | 67 | 0.220 |
Why?
| Esters | 1 | 2024 | 61 | 0.220 |
Why?
| Facial Hemiatrophy | 1 | 2023 | 1 | 0.220 |
Why?
| Costal Cartilage | 1 | 2023 | 2 | 0.220 |
Why?
| Tissue Scaffolds | 2 | 2023 | 179 | 0.210 |
Why?
| Amides | 1 | 2024 | 86 | 0.210 |
Why?
| Physical Stimulation | 1 | 2022 | 77 | 0.210 |
Why?
| Free Tissue Flaps | 1 | 2023 | 32 | 0.200 |
Why?
| Thalamus | 1 | 2022 | 74 | 0.200 |
Why?
| Immunosuppressive Agents | 5 | 2023 | 646 | 0.200 |
Why?
| Visual Pathways | 1 | 2022 | 44 | 0.190 |
Why?
| Skin Transplantation | 2 | 2014 | 57 | 0.190 |
Why?
| Manganese | 1 | 2022 | 55 | 0.190 |
Why?
| Rats, Inbred Lew | 6 | 2023 | 91 | 0.190 |
Why?
| Surgical Flaps | 2 | 2014 | 121 | 0.180 |
Why?
| Rectus Abdominis | 1 | 2020 | 9 | 0.180 |
Why?
| Rats, Inbred BN | 5 | 2023 | 52 | 0.170 |
Why?
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2020 | 16 | 0.170 |
Why?
| Parental Leave | 1 | 2019 | 17 | 0.170 |
Why?
| Sexism | 1 | 2020 | 44 | 0.170 |
Why?
| Physicians, Women | 1 | 2019 | 55 | 0.160 |
Why?
| Family Planning Services | 1 | 2019 | 68 | 0.160 |
Why?
| Career Choice | 1 | 2019 | 177 | 0.150 |
Why?
| Peripheral Nerves | 1 | 2018 | 64 | 0.150 |
Why?
| Recovery of Function | 2 | 2013 | 574 | 0.140 |
Why?
| Tissue Survival | 1 | 2016 | 13 | 0.140 |
Why?
| Retinal Ganglion Cells | 1 | 2017 | 92 | 0.140 |
Why?
| Leadership | 1 | 2020 | 292 | 0.140 |
Why?
| Hydrogels | 1 | 2023 | 573 | 0.130 |
Why?
| Refractory Period, Electrophysiological | 1 | 2016 | 5 | 0.130 |
Why?
| Graft Survival | 3 | 2023 | 446 | 0.130 |
Why?
| Surgeons | 1 | 2020 | 239 | 0.130 |
Why?
| Trigeminal Ganglion | 1 | 2016 | 21 | 0.130 |
Why?
| Evoked Potentials, Somatosensory | 1 | 2016 | 31 | 0.130 |
Why?
| Beneficence | 1 | 2016 | 18 | 0.130 |
Why?
| Central Nervous System | 1 | 2017 | 235 | 0.130 |
Why?
| Education, Medical, Graduate | 1 | 2019 | 368 | 0.130 |
Why?
| Lymphoproliferative Disorders | 1 | 2016 | 46 | 0.130 |
Why?
| Social Justice | 1 | 2016 | 67 | 0.120 |
Why?
| Cervicoplasty | 1 | 2014 | 1 | 0.120 |
Why?
| Postoperative Care | 1 | 2016 | 222 | 0.120 |
Why?
| Neck Injuries | 1 | 2014 | 18 | 0.120 |
Why?
| Extracellular Matrix | 1 | 2018 | 436 | 0.120 |
Why?
| Reaction Time | 1 | 2016 | 376 | 0.110 |
Why?
| Feasibility Studies | 1 | 2016 | 740 | 0.110 |
Why?
| Swine | 3 | 2022 | 700 | 0.110 |
Why?
| Tissue and Organ Procurement | 1 | 2016 | 228 | 0.110 |
Why?
| Patient Selection | 1 | 2016 | 641 | 0.100 |
Why?
| Transplantation, Isogeneic | 2 | 2009 | 17 | 0.100 |
Why?
| Allografts | 2 | 2023 | 122 | 0.100 |
Why?
| Swine, Miniature | 2 | 2022 | 71 | 0.090 |
Why?
| Burns | 1 | 2014 | 237 | 0.090 |
Why?
| Rats, Sprague-Dawley | 1 | 2016 | 2218 | 0.090 |
Why?
| Immune Tolerance | 2 | 2009 | 323 | 0.090 |
Why?
| Cyclosporine | 4 | 2013 | 161 | 0.080 |
Why?
| Humans | 10 | 2023 | 114709 | 0.080 |
Why?
| Disease Models, Animal | 2 | 2016 | 3535 | 0.080 |
Why?
| Facial Asymmetry | 1 | 2009 | 5 | 0.080 |
Why?
| Mandibulofacial Dysostosis | 1 | 2009 | 5 | 0.080 |
Why?
| Cleft Lip | 1 | 2009 | 31 | 0.080 |
Why?
| Craniosynostoses | 1 | 2009 | 28 | 0.080 |
Why?
| Nose | 1 | 2009 | 55 | 0.080 |
Why?
| Age Factors | 1 | 2016 | 2894 | 0.080 |
Why?
| Isoantibodies | 1 | 2009 | 57 | 0.080 |
Why?
| Cleft Palate | 1 | 2009 | 49 | 0.080 |
Why?
| Face | 1 | 2009 | 164 | 0.070 |
Why?
| Models, Animal | 1 | 2009 | 344 | 0.070 |
Why?
| Fascia | 1 | 2023 | 14 | 0.050 |
Why?
| Atrophy | 1 | 2023 | 152 | 0.050 |
Why?
| Abatacept | 1 | 2022 | 40 | 0.050 |
Why?
| Neoplasms | 1 | 2016 | 2097 | 0.050 |
Why?
| Optic Nerve | 1 | 2022 | 65 | 0.050 |
Why?
| Rabbits | 1 | 2023 | 733 | 0.050 |
Why?
| Sirolimus | 1 | 2022 | 181 | 0.050 |
Why?
| Chromatography, Liquid | 1 | 2022 | 347 | 0.040 |
Why?
| Internship and Residency | 2 | 2020 | 926 | 0.040 |
Why?
| Transplantation, Heterotopic | 1 | 2020 | 16 | 0.040 |
Why?
| Mammals | 1 | 2022 | 244 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2022 | 412 | 0.040 |
Why?
| Macaca | 1 | 2020 | 50 | 0.040 |
Why?
| Schwann Cells | 1 | 2020 | 27 | 0.040 |
Why?
| Maternal Health | 1 | 2019 | 42 | 0.040 |
Why?
| Contrast Media | 1 | 2022 | 345 | 0.040 |
Why?
| Delayed-Action Preparations | 1 | 2020 | 159 | 0.040 |
Why?
| Tissue Engineering | 1 | 2023 | 364 | 0.040 |
Why?
| Schools, Medical | 1 | 2020 | 120 | 0.040 |
Why?
| Stem Cells | 1 | 2023 | 546 | 0.040 |
Why?
| GAP-43 Protein | 1 | 2018 | 5 | 0.040 |
Why?
| Axons | 1 | 2020 | 177 | 0.040 |
Why?
| Intermediate Filaments | 1 | 2018 | 46 | 0.040 |
Why?
| Tensile Strength | 1 | 2018 | 88 | 0.040 |
Why?
| Needs Assessment | 1 | 2019 | 314 | 0.040 |
Why?
| Glycosaminoglycans | 1 | 2018 | 79 | 0.040 |
Why?
| Elastomers | 1 | 2017 | 24 | 0.040 |
Why?
| Faculty, Medical | 1 | 2020 | 228 | 0.040 |
Why?
| Polyesters | 1 | 2017 | 64 | 0.040 |
Why?
| Male | 7 | 2020 | 55609 | 0.030 |
Why?
| Neovascularization, Physiologic | 1 | 2018 | 173 | 0.030 |
Why?
| Societies, Medical | 1 | 2020 | 664 | 0.030 |
Why?
| Hyaluronic Acid | 1 | 2018 | 190 | 0.030 |
Why?
| Treatment Outcome | 2 | 2023 | 9088 | 0.030 |
Why?
| Wound Healing | 1 | 2018 | 258 | 0.030 |
Why?
| Collagen | 1 | 2018 | 415 | 0.030 |
Why?
| Cytokines | 1 | 2023 | 1841 | 0.030 |
Why?
| Back | 1 | 2014 | 10 | 0.030 |
Why?
| Time Factors | 2 | 2019 | 6116 | 0.030 |
Why?
| Tissue Expansion | 1 | 2014 | 11 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2017 | 296 | 0.030 |
Why?
| Child | 2 | 2014 | 18422 | 0.030 |
Why?
| Biocompatible Materials | 1 | 2018 | 369 | 0.030 |
Why?
| Fetus | 1 | 2018 | 700 | 0.030 |
Why?
| United States | 2 | 2020 | 12186 | 0.030 |
Why?
| Pulse Therapy, Drug | 1 | 2013 | 6 | 0.030 |
Why?
| Neural Conduction | 1 | 2013 | 78 | 0.030 |
Why?
| Sciatic Nerve | 1 | 2013 | 56 | 0.030 |
Why?
| Gene Expression | 1 | 2018 | 1421 | 0.030 |
Why?
| Attitude of Health Personnel | 1 | 2019 | 975 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2013 | 78 | 0.030 |
Why?
| Locomotion | 1 | 2013 | 80 | 0.030 |
Why?
| Dexamethasone | 1 | 2013 | 317 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2022 | 3053 | 0.020 |
Why?
| Acute Disease | 1 | 2013 | 911 | 0.020 |
Why?
| Specific Pathogen-Free Organisms | 1 | 2009 | 59 | 0.020 |
Why?
| Anti-Inflammatory Agents | 1 | 2013 | 447 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2019 | 4410 | 0.020 |
Why?
| Rats, Inbred WF | 1 | 2009 | 5 | 0.020 |
Why?
| Antilymphocyte Serum | 1 | 2009 | 60 | 0.020 |
Why?
| Femoral Vein | 1 | 2009 | 28 | 0.020 |
Why?
| Administration, Topical | 1 | 2009 | 138 | 0.020 |
Why?
| Anastomosis, Surgical | 1 | 2009 | 136 | 0.020 |
Why?
| Female | 3 | 2020 | 59523 | 0.020 |
Why?
| Pregnancy | 1 | 2019 | 5520 | 0.020 |
Why?
| Biomarkers | 1 | 2018 | 3408 | 0.020 |
Why?
| Femoral Artery | 1 | 2009 | 167 | 0.020 |
Why?
| Risk Factors | 1 | 2019 | 8634 | 0.020 |
Why?
| Adult | 2 | 2019 | 30554 | 0.020 |
Why?
| Cohort Studies | 1 | 2014 | 4895 | 0.010 |
Why?
| Skin | 1 | 2009 | 655 | 0.010 |
Why?
| Postoperative Complications | 1 | 2013 | 2128 | 0.010 |
Why?
| Young Adult | 1 | 2014 | 10472 | 0.010 |
Why?
| Retrospective Studies | 1 | 2014 | 12556 | 0.010 |
Why?
| Adolescent | 1 | 2014 | 17855 | 0.010 |
Why?
|
|
Washington's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|